RP Bio Inc. (KOSDAQ:314140)

RP Bio Statistics

Total Valuation

RP Bio has a market cap or net worth of KRW 61.62 billion. The enterprise value is 66.12 billion.

Market Cap	61.62B
Enterprise Value	66.12B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

RP Bio has 8.67 million shares outstanding. The number of shares has increased by 0.19% in one year.

Current Share Class	8.67M
Shares Outstanding	8.67M
Shares Change (YoY)	+0.19%
Shares Change (QoQ)	-0.19%
Owned by Insiders (%)	61.75%
Owned by Institutions (%)	n/a
Float	3.31M

Valuation Ratios

The trailing PE ratio is 12.59.

PE Ratio	12.59
Forward PE	n/a
PS Ratio	0.46
PB Ratio	0.58
P/TBV Ratio	0.59
P/FCF Ratio	6.65
P/OCF Ratio	4.29
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.84, with an EV/FCF ratio of 7.13.

EV / Earnings	13.52
EV / Sales	0.49
EV / EBITDA	5.84
EV / EBIT	13.89
EV / FCF	7.13

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.18.

Current Ratio	1.36
Quick Ratio	0.75
Debt / Equity	0.18
Debt / EBITDA	1.73
Debt / FCF	2.11
Interest Coverage	4.82

Financial Efficiency

Return on equity (ROE) is 4.72% and return on invested capital (ROIC) is 2.31%.

Return on Equity (ROE)	4.72%
Return on Assets (ROA)	1.91%
Return on Invested Capital (ROIC)	2.31%
Return on Capital Employed (ROCE)	4.21%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.86
Inventory Turnover	4.78

Taxes

Income Tax	-296.88M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.40% in the last 52 weeks. The beta is 0.62, so RP Bio's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+32.40%
50-Day Moving Average	7,413.40
200-Day Moving Average	6,189.23
Relative Strength Index (RSI)	44.12
Average Volume (20 Days)	72,329

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RP Bio had revenue of KRW 134.21 billion and earned 4.89 billion in profits. Earnings per share was 564.72.

Revenue	134.21B
Gross Profit	13.16B
Operating Income	4.76B
Pretax Income	4.59B
Net Income	4.89B
EBITDA	11.31B
EBIT	4.76B
Earnings Per Share (EPS)	564.72

Balance Sheet

The company has 15.08 billion in cash and 19.59 billion in debt, giving a net cash position of -4.50 billion or -519.79 per share.

Cash & Cash Equivalents	15.08B
Total Debt	19.59B
Net Cash	-4.50B
Net Cash Per Share	-519.79
Equity (Book Value)	105.90B
Book Value Per Share	12,266.56
Working Capital	15.14B

Cash Flow

In the last 12 months, operating cash flow was 14.35 billion and capital expenditures -5.08 billion, giving a free cash flow of 9.27 billion.

Operating Cash Flow	14.35B
Capital Expenditures	-5.08B
Free Cash Flow	9.27B
FCF Per Share	1,069.70

Margins

Gross margin is 9.80%, with operating and profit margins of 3.55% and 3.64%.

Gross Margin	9.80%
Operating Margin	3.55%
Pretax Margin	3.42%
Profit Margin	3.64%
EBITDA Margin	8.43%
EBIT Margin	3.55%
FCF Margin	6.91%

Dividends & Yields

RP Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.19%
Shareholder Yield	-0.19%
Earnings Yield	7.93%
FCF Yield	15.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RP Bio has an Altman Z-Score of 2.02 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.02
Piotroski F-Score	7